Liver disease, varices, and non-UGIH were excluded. Co-morbidities, medications, mortality, ASA Score, Glasgow Blatchford Score (GBS) and details Barasertib chemical structure of endoscopy (if performed) were examined. Results: There were 49 episodes over the period. The median age was 88.10 years. The main presentation of UGIH was malaena (44.90%). There were 30 episodes managed conservatively and 19 episodes which were managed through use of endoscopy. There was only 1 therapeutic endoscopy performed, with only 2 (10.53%, CI: ± 13.8%) being associated with a change in medical management of a patient. ASA score was similar between the 2 groups. An increasing ASA score was associated with an increased 30-day
mortality. A higher GBS did not correlate with an increase in 30-day mortality. Conclusion: Although the risks of endoscopy is low, its usefulness in elderly patients is limited and costly. Further studies are needed to HIF activation decide when it useful. ASA could be useful in determining those more at risk of dying within the next 30-days and potentially those with which it seems futile to perform endoscopy. Table 1: Endoscopic Benefits Endoscopy resulted in a change in management
10.53% (CI95: ±13.8%) Therapeutic endoscopy performed for UGIH 5.26% (CI95: ±10.04) CJ KIELY,1 J BENHAMU,2 TN EADE,2 V PATTULLO,1 D STIEL1 1Department of Gastroenterology and Hepatology, Royal North Shore Hospital, St Leonards, NSW, Australia, 2Department of Radiation Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia Introduction: Concurrent chemoradiotherapy (CCRT) is standard of care for locally advanced head and neck cancers. Treatment related toxicities (mucositis, dysphagia, nausea, xerostomia and dysgeusia) result in malnutrition and can limit CRRT dosing and scheduling1. Prophylactic gastrostomy tube (GT) insertion prior to
CCRT for head and neck cancers is an option to avoid treatment related malnutrition and 上海皓元 potential treatment breaks, as compared to reactive nasogastric tube (NGT) insertion2. Although GTs are generally well tolerated3, there are limited data on their safety and utility 4–5. Aims: To evaluate the safety, efficacy and tolerability of prophylactic GT insertion for patients undergoing CCRT for head and neck cancers in a large tertiary hospital setting. Methods: Data were available for 45 patients referred for GT insertion between 2007 and 2012. Clinical, biometric, biochemical and histological data were collected prospectively. Results: Mean age at commencement of therapy was 57 years ± standard deviation 10.5, and mean pre-treatment body mass index (BMI) was 26.7±4.9 kg/m2. Thirty-five patients (78%) underwent endoscopic GT insertion, nine (20%) surgical and one (2%) radiological insertion. Five patients were deemed unsuitable at endoscopy, requiring a second procedure.